TY - JOUR
T1 - Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells
AU - Nimmanapalli, Ramadevi
AU - Fuino, Lianne
AU - Bali, Purva
AU - Gasparetto, Maura
AU - Glozak, Michele
AU - Tao, Jianguo
AU - Moscinski, Lynn
AU - Smith, Clayton
AU - Wu, Jie
AU - Jove, Richard
AU - Atadja, Peter
AU - Bhalla, Kapil
PY - 2003/8/15
Y1 - 2003/8/15
N2 - Treatment with LAQ824 (Novartis Pharmaceutical, Inc.), a cinnamyl hydroxamic acid analogue inhibitor of histone deacetylases, depleted the mRNA and protein expression of Bcr-Abl in human chronic myeloid leukemia blast crisis (CML-BC) cells. Exposure to LAQ824 induced the expression of the cell cycle-dependent kinase inhibitors p21 and p27 and caused cell cycle G 1-phase accumulation and apoptosis of CML-BC cells. LAQ824 also induced acetylation of heat shock protein 90. This inhibited the chaperone association of Bcr-Abl with heat shock protein 90, thereby promoting the proteasomal degradation of Bcr-Abl. Cotreatment with LAQ824 increased imatinib mesylate-induced apoptosis of CML-BC cells. Additionally, LAQ824 down-regulated the levels of mutant Bcr-Abl possessing the T315I point mutation, as well as induced apoptosis of imatinib-refractory primary CML-BC cells. Therefore, LAQ824 may be a promising therapeutic agent in the treatment of imatinib-sensitive of -refractory human leukemia.
AB - Treatment with LAQ824 (Novartis Pharmaceutical, Inc.), a cinnamyl hydroxamic acid analogue inhibitor of histone deacetylases, depleted the mRNA and protein expression of Bcr-Abl in human chronic myeloid leukemia blast crisis (CML-BC) cells. Exposure to LAQ824 induced the expression of the cell cycle-dependent kinase inhibitors p21 and p27 and caused cell cycle G 1-phase accumulation and apoptosis of CML-BC cells. LAQ824 also induced acetylation of heat shock protein 90. This inhibited the chaperone association of Bcr-Abl with heat shock protein 90, thereby promoting the proteasomal degradation of Bcr-Abl. Cotreatment with LAQ824 increased imatinib mesylate-induced apoptosis of CML-BC cells. Additionally, LAQ824 down-regulated the levels of mutant Bcr-Abl possessing the T315I point mutation, as well as induced apoptosis of imatinib-refractory primary CML-BC cells. Therefore, LAQ824 may be a promising therapeutic agent in the treatment of imatinib-sensitive of -refractory human leukemia.
UR - http://www.scopus.com/inward/record.url?scp=0043016178&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0043016178&partnerID=8YFLogxK
M3 - Article
C2 - 12941844
AN - SCOPUS:0043016178
VL - 63
SP - 5126
EP - 5135
JO - Cancer research
JF - Cancer research
SN - 0008-5472
IS - 16
ER -